These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 12366730

  • 1. Preliminary results on pregnancy outcomes in women using lamotrigine.
    Tennis P, Eldridge RR, International Lamotrigine Pregnancy Registry Scientific Advisory Committee.
    Epilepsia; 2002 Oct; 43(10):1161-7. PubMed ID: 12366730
    [Abstract] [Full Text] [Related]

  • 2. Lamotrigine and the risk of malformations in pregnancy.
    Cunnington M, Tennis P, International Lamotrigine Pregnancy Registry Scientific Advisory Committee.
    Neurology; 2005 Mar 22; 64(6):955-60. PubMed ID: 15781807
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
    Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB.
    Am J Obstet Gynecol; 2000 Jan 22; 182(1 Pt 1):159-63. PubMed ID: 10649172
    [Abstract] [Full Text] [Related]

  • 6. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.
    Cunnington M, Ferber S, Quartey G, International Lamotrigine Pregnancy Registry Scientific Advisory Committee.
    Epilepsia; 2007 Jun 22; 48(6):1207-10. PubMed ID: 17381445
    [Abstract] [Full Text] [Related]

  • 7. Epilepsy and pregnancy: lamotrigine as main drug used.
    Sabers A, Dam M, A-Rogvi-Hansen B, Boas J, Sidenius P, Laue Friis M, Alving J, Dahl M, Ankerhus J, Mouritzen Dam A.
    Acta Neurol Scand; 2004 Jan 22; 109(1):9-13. PubMed ID: 14653845
    [Abstract] [Full Text] [Related]

  • 8. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.
    Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S.
    Arch Neurol; 2011 Oct 22; 68(10):1275-81. PubMed ID: 21670385
    [Abstract] [Full Text] [Related]

  • 9. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.
    Weston J, Bromley R, Jackson CF, Adab N, Clayton-Smith J, Greenhalgh J, Hounsome J, McKay AJ, Tudur Smith C, Marson AG.
    Cochrane Database Syst Rev; 2016 Nov 07; 11(11):CD010224. PubMed ID: 27819746
    [Abstract] [Full Text] [Related]

  • 10. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
    Ephross SA, Sinclair SM.
    Headache; 2014 Nov 07; 54(7):1158-72. PubMed ID: 24805878
    [Abstract] [Full Text] [Related]

  • 11. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
    Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F, EURAP study group.
    Lancet Neurol; 2011 Jul 07; 10(7):609-17. PubMed ID: 21652013
    [Abstract] [Full Text] [Related]

  • 12. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society.
    Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA, Wiebe S, Thurman D, Koppel BS, Kaplan PW, Robinson JN, Hopp J, Ting TY, Gidal B, Hovinga CA, Wilner AN, Vazquez B, Holmes L, Krumholz A, Finnell R, Hirtz D, Le Guen C, American Academy of Neurology, American Epilepsy Society.
    Epilepsia; 2009 May 07; 50(5):1237-46. PubMed ID: 19507301
    [Abstract] [Full Text] [Related]

  • 13. Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: Results from a pregnancy registry in South India.
    Thomas SV, Jose M, Divakaran S, Sankara Sarma P.
    Epilepsia; 2017 Feb 07; 58(2):274-281. PubMed ID: 28084641
    [Abstract] [Full Text] [Related]

  • 14. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.
    Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C.
    J Clin Neurosci; 2003 Sep 07; 10(5):543-9. PubMed ID: 12948456
    [Abstract] [Full Text] [Related]

  • 15. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?
    Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT, EUROCAT Antiepileptic Drug Working Group.
    Neurology; 2008 Sep 02; 71(10):714-22. PubMed ID: 18650491
    [Abstract] [Full Text] [Related]

  • 16. Newer-generation antiepileptic drugs and the risk of major birth defects.
    Mølgaard-Nielsen D, Hviid A.
    JAMA; 2011 May 18; 305(19):1996-2002. PubMed ID: 21586715
    [Abstract] [Full Text] [Related]

  • 17. Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
    Pariente G, Leibson T, Shulman T, Adams-Webber T, Barzilay E, Nulman I.
    CNS Drugs; 2017 Jun 18; 31(6):439-450. PubMed ID: 28434134
    [Abstract] [Full Text] [Related]

  • 18. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.
    Charlton RA, Weil JG, Cunnington MC, Ray S, de Vries CS.
    Drug Saf; 2011 Feb 01; 34(2):157-71. PubMed ID: 21247222
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.